Novo Nordisk Fights Generics with Price Cuts
Novo Nordisk India will cut prices on its diabetes and obesity drugs Ozempic and Wegovy by up to 48% starting April 1, 2026. The price of Ozempic's starting dose will drop 36%, and Wegovy's starting dose will fall 48%, bringing the weekly cost to about ₹1,415. This strategy is a direct response to Indian drugmakers launching cheaper semaglutide versions after Novo Nordisk's patents expired. The company stated the aim is to make therapies "more accessible to a larger section of people," but the move is crucial for defending market share against generics that cost as little as ₹1,290 per month. Ozempic and Wegovy generated over $30 billion globally in 2024, highlighting the importance of the Indian market.
Indian Rivals Rush to Market With Cheaper Generics
The Indian market is highly competitive following Novo Nordisk's patent expiry on March 20, 2026. Around 40 Indian companies are expected to launch semaglutide generics, offering prices 60-70% lower than the original. Major manufacturers like Sun Pharma, Dr. Reddy's Laboratories, Zydus Lifesciences, and Torrent Pharmaceuticals are among those introducing their own versions. The regulatory landscape also presents challenges; the Delhi High Court recently ordered Dr. Reddy's Laboratories to stop selling its 'Olymviq' brand due to its name sounding too similar to Ozempic. This case highlights increased scrutiny on drug branding in India, which could benefit established brands like Novo Nordisk. The Indian market for these diabetes and obesity drugs was valued at $110.55 million in 2024 and is expected to grow.
Pressure Mounts on Pricing and Profitability
The price cuts signal pressure on Novo Nordisk's premium pricing strategy. The company's current global Price-to-Earnings (P/E) ratio of approximately 9.94 is significantly below its five-year average, suggesting investor concerns over future growth and profit margins. Analysts anticipate potential downgrades to profit forecasts due to patent expirations and rising competition. Indian generics are offering prices below ₹1,500 per month, a stark contrast to Novo Nordisk's original range of ₹8,800-₹16,400, pointing to ongoing risks for profit margins. Despite Novo Nordisk stating it's "not in a game of chasing the price with generics," market conditions are forcing adjustments. A March 2, 2026, downgrade from Goldman Sachs, with a $41 price target, reflects investor caution regarding the company's profitability in this competitive environment.
Beyond Price Cuts: Partnerships and New Products
Novo Nordisk's strategy in India involves more than just price adjustments. The company has partnered with Emcure Pharmaceuticals to distribute a second Wegovy brand, Poviztra®, to improve access. Novo Nordisk also plans to introduce oral anti-obesity drugs, which could open new competitive avenues. Analysts offer a mixed view on the company's future, with general ratings hovering between 'Hold' and 'Buy'. Key to Novo Nordisk's success will be its capacity to manage pricing pressures, drive innovation, and leverage its brand strength in India's growing diabetes and obesity treatment market, projected to reach $190 million by 2033.